Summary of the characteristics of the subjects.
| Group 1 (NAT), N=17 (16%) |
Group 2 (Non-NAT), N=91 (84%) |
|
|---|---|---|
| Gender | ||
| Male | 17 (100%) | 88 (97%) |
| Female | 0 (0%) | 3 (3%) |
| Age | ||
| <2 years old | 0 (0%) | 0 (0%) |
| 2–15 years old | 14 (82%) | 72 (79%) |
| ≥16 years old | 3 (18%) | 19 (21%) |
| Diagnosis | ||
| Hemophilia A | 12 (71%) | 68 (75%) |
| Hemophilia B | 5 (29%) | 22 (24%) |
| Von Willebrand | 0 (0%) | 1 (1%) |
| Severity | ||
| Severe hemophilia | 11 (65%) | 54 (59%) |
| Moderate hemophilia | 6 (35%) | 30 (33%) |
| Mild hemophilia | 0 (0%) | 6 (7%) |
| VWD type 1 | 0 (0%) | 1 (1%) |
| Inhibitor FVIII | ||
| Low titer | 0 (0%) | 1 (1%) |
| High titer | 0 (0%) | 3 (3.3%) |
| Negative | 16 (94%) | 85 (93.4%) |
| History of inhibitor | 1 (6%) | 2 (2.2%) |
| Number of bagsa) during transfusion | ||
| 1–4 bags | 9 (53%) | 42 (46%) |
| 5–10 bags | 6 (35%) | 36 (40%) |
| >10 bags (volume of each bag ±50–180 mL) | 2 (12%) | 13 (14%) |
| Age of first transfusion | ||
| <2 years old | 6 (35%) | 34 (37%) |
| 2–15 years old | 11 (65%) | 57 (63%) |
| ≥16 years old | 0 (0%) | 0 (0%) |
| Major surgery | ||
| Yes | 0 (0%) | 18 (20%) |
| No | 17 (100%) | 73 (80%) |
a)Any type of blood component product.
Abbreviations: NAT, nucleic acid testing; VWD, Von Willebrand disease.
Blood Res 2022;57:129~134 https://doi.org/10.5045/br.2022.2021219
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd